Every S-3 that CAMP4 Therapeutics Corporation (CAMP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow CAMP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CAMP filings page.
CAMP4 Therapeutics Corporation is registering for resale up to 10,795,804 shares of common stock and 21,925,368 shares issuable upon exercise of 2026 pre-funded warrants held by existing investors. This is a secondary offering by selling stockholders; CAMP4 is not selling new shares.
The resale shares, assuming full warrant exercise, represented about 38.6% of common stock outstanding as of August 3, 2026, creating potential share overhang. CAMP4 will receive cash only if the 2026 pre-funded warrants are exercised, at an exercise price of $0.0001 per share, and intends to use any such proceeds to fund development of its lead ASO candidate CMP-002 for SYNGAP1-related disorder and for working capital.
The registration fulfills rights granted in a private placement completed in two closings that raised $46.7 million net initially and $50.1 million gross at the second closing, with shares and pre-funded warrants sold at prices around $1.53–$1.65 per share.
CAMP4 Therapeutics filed a shelf registration on Form S-3 to register up to $300,000,000 of common stock, preferred stock, warrants and debt securities, and added an at-the-market prospectus supplement to sell up to $100,000,000 of common stock from time to time.
Sales under the ATM will be made through Leerink Partners as sales agent under a Sales Agreement dated November 10, 2025, with a commission of up to 3.0% of gross proceeds. The company’s common stock trades on Nasdaq as “CAMP”; the last reported sale price was $4.25 on November 7, 2025. Net proceeds, if any, are intended for general corporate purposes, including R&D, clinical development, working capital and potential partnerships or in-licensing.
CAMP4 Therapeutics filed a resale registration covering 33,431,131 shares of Common Stock and 6,003,758 shares issuable upon exercise of its 2025 pre-funded warrants. The filing registers shares issued in a September 2025 private placement and 6,713,717 piggyback shares under an existing investors’ rights agreement.
The company is not offering any shares and will not receive proceeds from selling stockholder resales, other than any cash received upon warrant exercises. The 2025 pre-funded warrants carry a $0.0001 per-share exercise price and include beneficial ownership limits of 4.99% or 9.99% (adjustable to up to 19.99% with notice). As context, shares outstanding were 46,880,185 as of October 1, 2025. The company notes the registered resale shares represent approximately 69% of outstanding shares as of that date, which could pressure the stock if sold.